Xsensio, a Propel(x) portfolio company, is redefining health monitoring with Lab-on-Skin™ biosensing. The company’s ultra-thin wearable sensors provide real-time biochemical insights directly from the skin, making health data continuous, accessible, and non-invasive.
Xsensio technology enables chronic disease management, drug monitoring, sports performance tracking, and preventive care, bringing lab-grade biochemical analysis out of the clinic and onto a simple wearable patch.
Recent Highlights from Xsensio
Over the past year, Xsensio has achieved several key milestones:
- Recognized by TIME Magazine among the World’s Top HealthTech Companies 2025
- Launched a next-generation multiplex sensor, enabling multiple biomarkers to be tracked simultaneously from a single patch
- Expanded research collaborations with leading U.S. and European medical institutions to accelerate regulated healthcare applications
- Initiated new pharma pilot programs for therapeutic and drug-response monitoring
- Secured 10+ granted patents in biochemical sensing and system integration
Notable Investors
Xsensio is backed by prestigious investors, including Mayo Clinic Health System, Bracken Darrell (former CEO of Logitech), and Balz Roth & Oliver Müller (early investors in Lemoptix, acquired by Intel).
Leadership
Congratulations to CEO Esmeralda Megally, CTO Adrian M. Ionescu, and the Xsensio team for delivering continuous molecular-level insights to patients, clinicians, and consumers. Their work has the potential to transform how health is understood and managed in everyday life.
At Propel(x), we are proud to support founders who are translating deep-tech innovation into real-world health impact.
Register on Propel(x) to explore alternative investment opportunities like this:
https://www.propelx.com/
